469 related articles for article (PubMed ID: 29910159)
21. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
22. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
23. Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.
Mouri A; Kaira K; Yamaguchi O; Shiono A; Miura Y; Hashimoto K; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
Cancer Chemother Pharmacol; 2019 Oct; 84(4):873-880. PubMed ID: 31444618
[TBL] [Abstract][Full Text] [Related]
24. Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
Baldini E; Lunghi A; Cortesi E; Turci D; Signorelli D; Stati V; Melotti B; Ricciuti B; Frassoldati A; Romano G; Ceresoli GL; Illiano A; Verderame F; Fasola G; Ricevuto E; Marchetti P; Pinto C; Cartenì G; Scotti V; Tibaldi C; Fioretto L; Giannarelli D
Lung Cancer; 2020 Feb; 140():59-64. PubMed ID: 31881412
[TBL] [Abstract][Full Text] [Related]
25. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study.
Miura K; Sano Y; Niho S; Kawasumi K; Mochizuki N; Yoh K; Matsumoto S; Zenke Y; Ikeda T; Nosaki K; Kirita K; Udagawa H; Goto K; Kawasaki T; Hanada K
Thorac Cancer; 2021 Jul; 12(13):1983-1994. PubMed ID: 33990133
[TBL] [Abstract][Full Text] [Related]
26. Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.
Mishima Y; Fukaishi T; Inase N; Isogai S
Intern Med; 2019 Mar; 58(5):693-697. PubMed ID: 30449786
[TBL] [Abstract][Full Text] [Related]
27. Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer.
Maekura T; Naito M; Tahara M; Ikegami N; Kimura Y; Sonobe S; Kobayashi T; Tsuji T; Minomo S; Tamiya A; Atagi S
In Vivo; 2017; 31(5):1035-1039. PubMed ID: 28882978
[TBL] [Abstract][Full Text] [Related]
28. Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma.
Yano S; Ashida K; Nagata H; Ohe K; Wada N; Takeichi Y; Hanada Y; Ibayashi Y; Wang L; Sakamoto S; Sakamoto R; Uchi H; Shiratsuchi M; Furue M; Nomura M; Ogawa Y
BMC Endocr Disord; 2018 Jun; 18(1):36. PubMed ID: 29884162
[TBL] [Abstract][Full Text] [Related]
29. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
Cortellini A; Chiari R; Ricciuti B; Metro G; Perrone F; Tiseo M; Bersanelli M; Bordi P; Santini D; Giusti R; Grassadonia A; Di Marino P; Tinari N; De Tursi M; Zoratto F; Veltri E; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Iacono D; Migliorino MR; Porzio G; Cannita K; Ficorella C; Buti S
Clin Lung Cancer; 2019 Jul; 20(4):237-247.e1. PubMed ID: 30885550
[TBL] [Abstract][Full Text] [Related]
30. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
[TBL] [Abstract][Full Text] [Related]
31. Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab.
Funazo TY; Nomizo T; Ozasa H; Tsuji T; Yasuda Y; Yoshida H; Sakamori Y; Nagai H; Hirai T; Kim YH
Sci Rep; 2019 Nov; 9(1):17085. PubMed ID: 31745135
[TBL] [Abstract][Full Text] [Related]
32. Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis.
Ando T; Ueda A; Ogawa K; Motoo I; Kajiura S; Nakajima T; Hirano K; Okumura T; Tsukada K; Hara T; Suzuki N; Nakada N; Horikawa N; Fujii T; Yasuda I
In Vivo; 2021; 35(1):475-482. PubMed ID: 33402499
[TBL] [Abstract][Full Text] [Related]
33. Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma.
Kobayashi K; Iikura Y; Hiraide M; Yokokawa T; Aoyama T; Shikibu S; Hashimoto K; Suzuki K; Sato H; Sugiyama E; Tajima M; Hama T
In Vivo; 2020; 34(5):2647-2652. PubMed ID: 32871795
[TBL] [Abstract][Full Text] [Related]
34. Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer.
Sabatier R; Nicolas E; Paciencia M; Jonville-Béra AP; Madroszyk A; Cecile M; Braticevic C; Duran S; Tassy L; Rouby F; Micallef J; Rousseau F
J Geriatr Oncol; 2018 Sep; 9(5):494-500. PubMed ID: 29530494
[TBL] [Abstract][Full Text] [Related]
35. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer.
Luo J; Martucci VL; Quandt Z; Groha S; Murray MH; Lovly CM; Rizvi H; Egger JV; Plodkowski AJ; Abu-Akeel M; Schulze I; Merghoub T; Cardenas E; Huntsman S; Li M; Hu D; Gubens MA; Gusev A; Aldrich MC; Hellmann MD; Ziv E
Clin Cancer Res; 2021 Sep; 27(18):5131-5140. PubMed ID: 34244291
[TBL] [Abstract][Full Text] [Related]
37. Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.
Krefting F; Basara N; Schütte W; Späth-Schwalbe E; Alt J; Thiel S; Kimmich M; Fischer JR; Kurz S; Griesinger F; Christoph DC
Oncol Res Treat; 2019; 42(5):243-255. PubMed ID: 30995666
[TBL] [Abstract][Full Text] [Related]
38. [Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment].
Imai Y; Tanaka M; Fujii R; Uchitani K; Okazaki K
Yakugaku Zasshi; 2019; 139(3):491-495. PubMed ID: 30828027
[TBL] [Abstract][Full Text] [Related]
39. Predictors of immunotherapy-induced immune-related adverse events.
Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
[TBL] [Abstract][Full Text] [Related]
40. Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: Postmarketing surveillance.
Yamamoto N; Nakanishi Y; Gemma A; Nakagawa K; Sakamoto T; Akamatsu A; Ohe Y
Cancer Sci; 2021 Nov; 112(11):4692-4701. PubMed ID: 34431585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]